☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Akebia
Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD
May 26, 2023
Akebia Receives the MHRA’s Approval of Vafseo for Symptomatic Anemia Associated with Chronic Kidney Disease
May 23, 2023
Akebia Receives EC’s Marketing Authorisation of Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia
April 26, 2023
Akebia Receives EMA’s CHMP Positive Opinion of Vafseo (vadadustat) for Symptomatic Anaemia Associated with Chronic Kidney Disease
February 24, 2023
Akebia Amended and Restated License Agreement with Vifor Pharma to Launch Vadadustat in the US
February 23, 2022
Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020
February 7, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.